智通财经网·2026-02-11 10:12Core Viewpoint - The company has entered into a global exclusive licensing agreement with Madrigal Pharmaceuticals for the development of six preclinical siRNA therapies targeting metabolic dysfunction-related fatty liver disease (MASH) [1][2] Group 1: Agreement Details - The agreement grants Madrigal exclusive global rights to utilize the company's RiboGalSTARTM and siRNA chemical modification platform for the development, production, and commercialization of several preclinical single-target and dual-target siRNA assets [1] - The company will receive an upfront payment of $60 million, with potential milestone payments totaling up to $4.4 billion, in addition to potential royalties on net sales [1] Group 2: Strategic Implications - This collaboration will leverage the company's proven liver-targeting RiboGalSTARTM platform to develop new therapies for MASH, marking a significant milestone in the company's path to becoming a leading global innovator in siRNA [2] - The partnership aims to accelerate the company's global development and commercialization strategy, addressing unmet medical needs for MASH patients with more targeted and effective therapies [2]